{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:46:48Z","timestamp":1791521208156,"version":"4.3.4"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\n Background<\/jats:title>\n In the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs), vancomycin stands as the prevalent therapeutic agent. Daptomycin remains an alternative antibiotic to treat MRSA BSIs in cases where vancomycin proves ineffective. However, studies have conflicted on whether daptomycin is more effective than vancomycin among patients with MRSA BSI.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the effectiveness of daptomycin and vancomycin for the prevention of mortality among adult patients with MRSA BSI.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Systematic searches of databases were performed, including Embase, PubMed, Web of Science, and Cochrane Library. The Newcastle Ottawa Scale (NOS) and Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) were used to assess the quality of individual observational and randomized control studies, respectively. Pooled odd ratios were calculated using random effects models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twenty studies were included based on\n a priori<\/jats:italic>\n set inclusion and exclusion criteria. Daptomycin treatment was associated with non-significant lower mortality odds, compared to vancomycin treatment (OR = 0.81; 95% CI, 0.62, 1.06). Sub-analyses based on the time patients were switched from another anti-MRSA treatment to daptomycin demonstrated that switching to daptomycin within 3 or 5 days was significantly associated with 55% and 45% decreased odds of all-cause mortality, respectively. However, switching to daptomycin any time after five days of treatment was not significantly associated with lower odds of mortality. Stratified analysis based on vancomycin minimum inhibitory concentration (MIC) revealed that daptomycin treatment among patients infected with MRSA strains with MIC\u22651 mg\/L was significantly associated with 40% lower odds of mortality compared to vancomycin treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Compared with vancomycin, an early switch from vancomycin to daptomycin was significantly associated with lower odds of mortality. In contrast, switching to daptomycin at any time only showed a trend towards reduced mortality, with a non-significant association. Therefore, the efficacy of early daptomycin use over vancomycin against mortality among MRSA BSIs patients may add evidence to the existing literature in support of switching to daptomycin early over remaining on vancomycin. More randomized and prospective studies are needed to assess this association.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0293423","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T13:28:46Z","timestamp":1708522126000},"page":"e0293423","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-1085","authenticated-orcid":true,"given":"Yau","family":"Adamu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Puig-Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir","family":"Dabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-0093","authenticated-orcid":true,"given":"Marin L.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"9","key":"pone.0293423.ref001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections\u2014United States.","volume":"68","author":"AP Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"pone.0293423.ref002","doi-asserted-by":"crossref","first-page":"ofab585","DOI":"10.1093\/ofid\/ofab585","article-title":"Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Hospitalizations: National Inpatient Sample, 2016\u20132019.","volume":"9","author":"EY Klein","year":"2022","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"pone.0293423.ref003","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"JN Steenbergen","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"pone.0293423.ref004","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1086\/518452","article-title":"Counterpoint: Vancomycin and Staphylococcus aureus\u2014An antibiotic enters obsolescence","volume":"44","author":"S. Deresinski","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pone.0293423.ref005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12879-019-4077-1","article-title":"Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis.","volume":"19","author":"P Gaudard","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"9","key":"pone.0293423.ref006","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"TP Lodise","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"8","key":"pone.0293423.ref007","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.00257-08","article-title":"Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus","volume":"52","author":"SN Leonard","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0293423.ref008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary","volume":"52","author":"C Liu","year":"2011","journal-title":"Clinical Infectious Diseases"},{"issue":"13","key":"pone.0293423.ref009","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of staphylococcus aureus bacteremia: A review.","volume":"312","author":"TL Holland","year":"2014","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"issue":"12","key":"pone.0293423.ref010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","article-title":"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin","volume":"15","author":"KS Estes","year":"2010","journal-title":"Eur J Med Res"},{"issue":"4","key":"pone.0293423.ref011","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"BH Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0293423.ref012","first-page":"282","article-title":"Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.","volume":"33","author":"NH Chan Tompkins","year":"2008","journal-title":"P t."},{"key":"pone.0293423.ref013","author":"U.S. Food and Drug Administration","year":"2016","journal-title":"First Generic Drug Approvals"},{"issue":"15","key":"pone.0293423.ref014","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ajhp\/zxab123","article-title":"Validity of 2020 vancomycin consensus recommendations and further guidance for practical application.","volume":"78","author":"MJ Rybak","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"suppl_1","key":"pone.0293423.ref015","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/ofid\/ofx162.074","article-title":"The Emperor\u2019s New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE).","volume":"4","author":"TP Lodise","year":"2017","journal-title":"Open Forum Infectious Diseases."},{"issue":"5","key":"pone.0293423.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy093","article-title":"Management practices for methicillin-resistant staphylococcus aureus bacteremia by adult infectious diseases physicians.","volume":"5","author":"N Banniettis","year":"2018","journal-title":"Open Forum Infectious Diseases."},{"issue":"4","key":"pone.0293423.ref017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Annals of internal medicine"},{"key":"pone.0293423.ref018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"pone.0293423.ref019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2288-11-29","article-title":"A worked example of \"best fit\" framework synthesis: A systematic review of views concerning the taking of some potential chemopreventive agents.","volume":"11","author":"C Carroll","year":"2011","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"pone.0293423.ref020","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions.","volume":"123","author":"WS Richardson","year":"1995","journal-title":"ACP journal club"},{"issue":"8","key":"pone.0293423.ref021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","volume":"23","author":"PN Harris","year":"2017","journal-title":"Clinical microbiology and infection"},{"key":"pone.0293423.ref022","author":"GA Wells","year":"2000","journal-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"pone.0293423.ref023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application.","volume":"126","author":"S Minozzi","year":"2020","journal-title":"Journal of clinical epidemiology"},{"issue":"1","key":"pone.0293423.ref024","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2702-8","article-title":"A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations\u2014results of a prematurely terminated study.","volume":"19","author":"S Kalimuddin","year":"2018","journal-title":"Trials."},{"issue":"7","key":"pone.0293423.ref025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1248\/bpb.b16-00255","article-title":"Analysis of staphylococcal toxins and clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia","volume":"39","author":"M Maeda","year":"2016","journal-title":"Biological and Pharmaceutical Bulletin"},{"issue":"1","key":"pone.0293423.ref026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant staphylococcus aureus with a high vancomycin minimum inhibitory concentration: A case-control study","volume":"54","author":"CL Moore","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"pone.0293423.ref027","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: A matched cohort study","volume":"56","author":"KP Murray","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0293423.ref028","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant staphylococcus aureus (MRSA) bloodstream infections.","volume":"72","author":"ML Schweizer","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"pone.0293423.ref029","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cid\/ciu165","article-title":"The efficacy of daptomycin versus vancomycin for methicillin-resistant staphylococcus aureus bloodstream infection in patients with impaired renal function","volume":"58","author":"A Weston","year":"2014","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pone.0293423.ref030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg\/L: a Multicenter Evaluation.","volume":"38","author":"PA Moise","year":"2016","journal-title":"Clinical therapeutics."},{"issue":"1","key":"pone.0293423.ref031","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MAJ.0000000000000338","article-title":"Evaluation of the treatment of methicillin-resistant staphylococcus aureus bacteremia","volume":"349","author":"JB Usery","year":"2015","journal-title":"American Journal of the Medical Sciences"},{"issue":"12","key":"pone.0293423.ref032","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: A prospective study from the international collaboration on endocarditis","volume":"57","author":"M Carugati","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7","key":"pone.0293423.ref033","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"VG Fowler","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"pone.0293423.ref034","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgar.2018.03.007","article-title":"Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia","volume":"14","author":"J Ruiz","year":"2018","journal-title":"Journal of Global Antimicrobial Resistance"},{"issue":"3","key":"pone.0293423.ref035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijantimicag.2012.10.019","article-title":"Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations.","volume":"41","author":"CW Cheng","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"pone.0293423.ref036","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40121-021-00401-1","article-title":"Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection.","volume":"10","author":"A Barlow","year":"2021","journal-title":"Infectious Diseases and Therapy."},{"issue":"10","key":"pone.0293423.ref037","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"KC Claeys","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"pone.0293423.ref038","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/phar.1220","article-title":"Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant staphylococcus aureus bacteremia.","volume":"33","author":"R Kullar","year":"2013","journal-title":"Pharmacotherapy."},{"key":"pone.0293423.ref039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"S Arshad","year":"2017","journal-title":"International Journal of Infectious Diseases"},{"issue":"6","key":"pone.0293423.ref040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: Subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"SJ Rehm","year":"2008","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"pone.0293423.ref041","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab327","article-title":"Clinical Outcomes with Definitive Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia with Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy with Vancomycin, Daptomycin, or Ceftaroline.","volume":"8","author":"CN Nichols","year":"2021","journal-title":"Open Forum Infectious Diseases."},{"key":"pone.0293423.ref042","first-page":"65","article-title":"Daptomycin vs. glycopeptides for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A multicentre cohort study","volume":"18","author":"LE L\u00f3pez-Cort\u00e9s","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"key":"pone.0293423.ref043","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/ofid\/ofy210.899","article-title":"Daptomycin\/ceftaroline in combination vs. vancomycin for the treatment of methicillin-resistant staphylococcus aureus bacteremia","volume":"5","author":"M Fox","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"pone.0293423.ref044","doi-asserted-by":"crossref","first-page":"S716","DOI":"10.1093\/ofid\/ofac492.1464","article-title":"Evaluation of De-Escalation Options after Combination Daptomycin and Ceftaroline Therapy for Persistent MRSA Bacteremia.","volume":"9","author":"RD Carroll","year":"2022","journal-title":"Open Forum Infectious Diseases."},{"key":"pone.0293423.ref045","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","author":"JP Higgins","year":"2008","journal-title":"Cochrane handbook for systematic reviews of interventions"},{"issue":"4","key":"pone.0293423.ref046","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"Journal of clinical epidemiology"},{"issue":"10","key":"pone.0293423.ref047","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"2019","author":"M Cumpston","year":"2019","journal-title":"The Cochrane database of systematic reviews."},{"issue":"8","key":"pone.0293423.ref048","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10081014","article-title":"Daptomycin versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus bloodstream infection with or without endocarditis: A systematic review and meta-analysis.","volume":"10","author":"AE Maraolo","year":"2021","journal-title":"Antibiotics"},{"issue":"4","key":"pone.0293423.ref049","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040714","article-title":"Efficacy and Safety of Daptomycin versus Vancomycin for Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus with Vancomycin Minimum Inhibitory Concentration > 1 \u03bcg\/mL: A Systematic Review and Meta-Analysis.","volume":"14","author":"M Samura","year":"2022","journal-title":"Pharmaceutics."},{"issue":"11","key":"pone.0293423.ref050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-19","article-title":"Is daptomycin plus ceftaroline associated with better clinical outcomes than standard of care monotherapy for staphylococcus aureus bacteremia?","volume":"63","author":"AC Kalil","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"pone.0293423.ref051","article-title":"Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections","volume":"61","author":"K-H Song","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"15","key":"pone.0293423.ref052","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1001\/jama.2014.6364","article-title":"Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis","volume":"312","author":"AC Kalil","year":"2014","journal-title":"Jama"},{"issue":"1","key":"pone.0293423.ref053","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/dkn439","article-title":"Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"63","author":"SN Leonard","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"10","key":"pone.0293423.ref054","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.","volume":"36","author":"G Sakoulas","year":"2014","journal-title":"Clinical therapeutics."},{"issue":"1","key":"pone.0293423.ref055","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments.","volume":"7","author":"EK McCreary","year":"2020","journal-title":"Open Forum Infectious Diseases."},{"issue":"2","key":"pone.0293423.ref056","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"KE Barber","year":"2015","journal-title":"Journal of Antimicrobial Chemotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T13:29:19Z","timestamp":1708522159000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293423"}},"subtitle":[],"editor":[{"given":"Mohamed O.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293423","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}